A federal court in Pennsylvania ruled that CVS Caremark must pay $95 million for allegedly causing Medicare to overpay for prescription drugs through improper conduct. The case centers on accusations of fraudulent practices related to reimbursement claims. This verdict adds to increasing scrutiny of pharmacy benefit managers and their role in healthcare costs. CVS is expected to respond to the judgment as legal proceedings continue.